RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced

FDA approved blinded, multi-centric Phase-3 trial (NCTsrc6489src28) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU…
Read More

About Author

Stephania Culton

See author's posts

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced

About Author

Stephania Culton

SBRT vs Hypofractionated Radiotherapy for Stage I NSCLC?

Ghost Fat: The Unseen Consequences of Weight Loss

FDA Antidepressant Warnings Tied to Increase in Suicidality

SBRT vs Hypofractionated Radiotherapy for Stage I NSCLC?

Why Residents Are Joining Unions in Droves

ILD Linked to Worse Outcomes in Pulmonary Embolism

Study finds common breast cancer treatments may speed aging process

FDA Antidepressant Warnings Tied to Increase in Suicidality

The 8 Best Sweatsuits for Men, Tested by Style Editors

New study shows a single experimental shot reduces HIV levels 1,000-fold

Binge drinking more common in sexual- and gender-minority students

ADHD symptoms in autistic children linked to neighborhood conditions

HbA1c stability tied to lower risk for Alzheimer’s disease and related dementias

SBRT vs Hypofractionated Radiotherapy for Stage I NSCLC?

Why Residents Are Joining Unions in Droves

ILD Linked to Worse Outcomes in Pulmonary Embolism

Study finds common breast cancer treatments may speed aging process

FDA Antidepressant Warnings Tied to Increase in Suicidality

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories